Activist investor Elliott Management continues to push for a change in leadership at GlaxoSmithKline ahead of the planned 2022 split of the company. Without specifically calling her out, the investment group made it clear that current Chief Executive Officer Emma Walmsley should not continue to lead.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,